1. Outliers and Patients with Adverse Drug Reactions

   • I. Ralph Edwards

   Editorial 19 October 2012 Pages: 623 - 624

2. Do Nanomedicines Require Novel Safety Assessments to Ensure their Safety for Long-Term Human Use?

   • Peter Hoet
   • Barbara Legiest
   • Benoit Nemery

   Current Opinion 19 October 2012 Pages: 625 - 636

3. Serenoa repens (Saw Palmetto)

   • Taofikat B. Agbabiaka
   • Max H. Pittler
   • Edzard Ernst

   Review Article 19 October 2012 Pages: 637 - 647

   

4. Amyotrophic Lateral Sclerosis-Like Conditions in Possible Association with Cholesterol-Lowering Drugs

   • Beatrice A. Golomb
   • Edwin K. Kwon
   • Marcella A. Evans

   Short Communication 19 October 2012 Pages: 649 - 661

   

5. Application of the Bow-Tie Model in Medication Safety Risk Analysis

   • Peter C. Wierenga
   • Loraine Lie-A-Huen
   • Susanne M. Smorenburg

   Original Research Article 19 October 2012 Pages: 663 - 673

   

6. Thiazolidinediones and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus

   • Fei-Yuan Hsiao
   • Weng-Foung Huang
   • Yi-Wen Tsai

   Original Research Article 19 October 2012 Pages: 675 - 690

   

7. Remedies Containing Asteraceae Extracts

   • Elke Jeschke
   • Thomas Ostermann
   • Harald Matthes

   Original Research Article 19 October 2012 Pages: 691 - 706

   

8. Comment on “Drug-Induced Thrombocytopenia: An Updated Systematic Review”

   • Bart L. De Keulenaer
   • Chan Y. Cheah

   Correspondence 19 October 2012 Pages: 707 - 707

9. The Authors’ Reply

   • James N. George

   Correspondence 19 October 2012 Pages: 708 - 708